Related by context. All words. (Click for frequent words.) 63 cyclophilin inhibitor 61 Phase Ib clinical 61 PDE4 inhibitor 60 IPL# 59 Omacetaxine 59 PSN# [002] 59 ENMD # 59 Phase 1b clinical 59 ARRY 59 AEGR 59 INCB# [001] 58 PRTX 58 highly selective inhibitor 58 CCR5 antagonist 58 phase IIa clinical 58 polymerase inhibitor 58 orally bioavailable 57 RG# ITMN 57 Tyrima 57 TG# [003] 57 PRT# 57 Phase Ib study 57 Hsp# inhibitors 57 vascular disrupting agent 57 davunetide intranasal AL 57 fosbretabulin 57 bendamustine 57 Phase Ib II 57 VQD 57 ORMD 57 investigational oral 57 metastatic hormone refractory 57 MORAb 56 Phase 1b trial 56 MEK inhibitor 56 Hsp# inhibitor 56 preclinically 56 KRN# 56 favorable pharmacokinetic profile 56 GLYX 56 vidofludimus 56 nucleoside analog 56 preclinical efficacy 56 PARP inhibitor 56 Cloretazine ® 56 TRO# 56 depsipeptide 56 HDACi 56 orally administered inhibitor 56 investigational hepatitis C 56 NXL# 56 PRX # 56 protein kinase inhibitor 56 cathepsin K inhibitor 56 pomalidomide 55 Hsp# Inhibitor 55 GW# [003] 55 sodium glucose cotransporter 55 CRx 55 Vilazodone 55 targeting CD# 55 Sym# 55 seliciclib CYC# 55 phase Ib 55 ganetespib 55 retapamulin 55 receptor tyrosine kinase inhibitor 55 oral prodrug 55 AEZS 55 SCH # 55 TPI ASM8 55 Phase Ib 55 Phase III randomized controlled 55 phase IIb clinical 55 varespladib 55 oral antiviral 55 inhibitor RG# 55 MT# MEDI 55 novel histone deacetylase 55 relapsed MM 55 HIV integrase inhibitor 55 pharmacokinetics PK 55 NKTR 55 sunitinib malate 55 Onconase 55 Xanafide 55 beta 1a 55 Perifosine 55 PS# [001] 55 omacetaxine mepesuccinate 55 HSP# inhibitor 55 selective antagonist 55 liposomal formulation 54 OMP #M# 54 blinded randomized placebo controlled 54 desvenlafaxine succinate 54 OXi# 54 phase IIa 54 BMN 54 PI3K inhibitor 54 Panzem R 54 selective androgen receptor modulator 54 Phase Ia 54 JVRS 54 antibody MAb 54 pan HDAC inhibitor 54 Pimavanserin 54 neratinib 54 lintuzumab 54 BAL# [002] 54 romidepsin 54 Archexin 54 novel immunomodulatory 54 Cloretazine 54 HGS# 54 obatoclax 54 S/GSK# 54 phase IIb trial 54 ACHN 54 selective inhibitor 54 polymerase inhibitors 54 long acting muscarinic 54 dose escalation Phase 54 CHAMPION PCI 54 Traficet EN 54 Phase 2a trial 54 non nucleoside inhibitor 54 GSK# [001] 54 pertuzumab 54 Romidepsin 54 DermaVir Patch 54 JAK inhibitor 54 hour bronchodilation 54 ALN HPN 54 HCV protease inhibitor 54 torezolid 54 Phase 1a clinical 54 RNAi therapeutic targeting 54 Phase IIa clinical 54 intranasal formulation 54 INCB# [003] 54 Lu AA# 54 histone deacetylase HDAC inhibitor 53 PEG IFN 53 Debio 53 trastuzumab emtansine T DM1 53 ascending doses 53 Akt inhibitor 53 pharmacokinetic PK study 53 phase IIb 53 investigational drug 53 investigational compound 53 investigational humanized monoclonal antibody 53 Cloretazine R 53 Preclinical studies 53 HDAC inhibitor 53 darinaparsin ZIO 53 CEQ# 53 Silodosin 53 phase 2a 53 Squalamine 53 Luteinizing Hormone Releasing Hormone 53 lexidronam injection 53 Phase #/#a 53 CCX# 53 IAP inhibitors 53 placebo controlled clinical 53 Amrubicin 53 multicenter Phase III 53 safety tolerability pharmacokinetic 53 phase Ib clinical 53 nab paclitaxel 53 investigational protease inhibitor 53 boosted protease inhibitor 53 COPAXONE R 53 elvucitabine 53 BAY #-# 53 Phase IIa trial 53 Bezielle 53 MabCampath 53 serotonin norepinephrine reuptake inhibitor 53 mapatumumab 53 evaluating tivozanib 53 ara C 53 PSMA ADC 53 lumiliximab 53 analgesic efficacy 53 ataluren 53 Ceflatonin R 53 alagebrium 53 nucleotide analog 53 BNC# 53 Denufosol 53 ceftazidime 53 Phase 2a clinical 53 resminostat 53 HCV protease 53 CIMZIA TM certolizumab pegol 53 temsirolimus 53 maturation inhibitor 53 iobenguane 53 alvespimycin 53 CD# monoclonal antibody 53 YONDELIS 53 CDK inhibitor 53 SARMs 53 RhuDex ® 53 Androxal TM 53 HCV polymerase inhibitor 53 remission induction 53 zileuton 53 SinuNase ™ 53 EZN 53 VNP#M 53 ILUVIEN ® 53 pharmacodynamic properties 53 tezampanel 52 dexamethasone Decadron 52 metastatic renal cell carcinoma 52 R roscovitine 52 Zenvia ™ 52 TBC# 52 potent antiproliferative 52 Phase 2b clinical trials 52 prucalopride 52 tipifarnib 52 axitinib 52 KNS # 52 vascular disrupting agents 52 bevacizumab Avastin ® 52 TRX1 52 MEK inhibitors 52 Oral NKTR 52 Tesmilifene 52 5 HT2A inverse 52 PD LID 52 selectively inhibits 52 clinical pharmacology studies 52 AKT inhibitor 52 solithromycin 52 ELACYT 52 RNA antagonist 52 MIRCERA 52 ISIS # 52 NVA# 52 ocular formulation 52 radiation sensitizer 52 MAGE A3 ASCI 52 Phase IIa trials 52 AVONEX ® 52 pharmacodynamic profile 52 Voreloxin 52 renin inhibitor 52 Mipomersen 52 RezularTM 52 ITMN 52 EQUIP OB 52 ATL# [001] 52 virus HCV protease inhibitor 52 fluoropyrimidine 52 CTAP# Capsules 52 AEG# 52 cell lymphoma CTCL 52 PEGylated interferon beta 1a 52 Dapagliflozin 52 WX UK1 52 relapsing multiple sclerosis 52 Dyloject TM 52 ART# 52 zonisamide SR 52 huN# DM1 52 sorafenib tablets 52 imatinib mesylate 52 HuLuc# 52 Symadex 52 DMAG 52 kinase inhibitor 52 REMUNE R 52 Guanilib 52 Phase IIA 52 multicenter Phase II 52 trastuzumab Herceptin ® 52 4SC 52 antiviral activity 52 ALN TTR 52 ARIKACE ™ 52 mertansine 52 anti amnesic 52 PANVAC VF 52 pradefovir 52 Nexavar ® 52 Alzhemed TM 52 Apoptone 52 teriflunomide 52 HDAC Inhibitor 52 PI3K/Akt pathway inhibitor 52 Aflibercept 52 TKB# 52 Ozarelix 52 CA4P 52 EOquin 52 Cethromycin 52 Phase 1b clinical trials 52 RH1 52 phase IIIb 52 paclitaxel poliglumex 52 teduglutide 52 sorafenib Nexavar 52 JAK2 inhibitors 52 HCV NS5B polymerase 52 viral kinetics 52 non nucleoside 52 AQ4N 52 pharmacokinetic PK 52 diabetic neuropathic pain 51 double blinded randomized 51 Safinamide 51 Azedra 51 JAK1 51 erlotinib Tarceva ® 51 reversible inhibitor 51 Microplasmin 51 oritavancin 51 IMiDs R 51 dose limiting toxicities 51 alemtuzumab Campath 51 familial amyloidotic polyneuropathy FAP 51 Hyphanox 51 nucleoside 51 Annamycin 51 GLP toxicology studies 51 rilonacept 51 Ceflatonin 51 Zybrestat 51 antiviral efficacy 51 Tanespimycin 51 CRLX# 51 Daclizumab 51 Hedgehog Pathway Inhibitor 51 CYC# 51 cariprazine 51 angiotensin receptor blocker ARB 51 Laquinimod 51 viral kinetic 51 Spiegelmer ® 51 PXD# 51 Phase 2a Clinical Trial 51 visilizumab 51 LEVADEX 51 CCR2 51 ATL# [002] 51 Phase IIb trials 51 Phase 1b 51 proteasome inhibitor 51 INGN 51 Tarceva TM 51 ELND# 51 placebo controlled Phase III 51 ongoing Phase 1b 51 receptor partial agonist 51 multi kinase inhibitor 51 non nucleoside HCV 51 CBLC# 51 Dalbavancin 51 doxorubicin docetaxel 51 castrate resistant prostate cancer 51 humanized monoclonal 51 protease inhibitor PI 51 Alfacell proprietary ribonuclease 51 tubulin inhibitor 51 PEG SN# 51 R#/MEM # 51 HCV protease inhibitors 51 desvenlafaxine 51 HCV replicon 51 elotuzumab 51 ICA # 51 HQK 51 Maribavir 51 Tolvaptan 51 otelixizumab 51 Amplimexon 51 novel prodrug 51 regorafenib 51 BRAF inhibitor 51 selective agonist 51 pharmacodynamic PD 51 small molecule inhibitor 51 oral candidiasis 51 thymalfasin 51 IGF 1R inhibitor 51 riociguat 51 Shigamabs ® 51 cyclophilin inhibitors 51 mitogen activated ERK kinase 51 MAP# 51 PNP inhibitor 51 CD3 monoclonal antibody 51 phase IIb study 51 pharmacokinetic pharmacodynamic 51 Phase 2b 51 CUDC 51 Saxagliptin 51 humanized monoclonal antibody 51 Phase IIIb clinical 51 MTP inhibitor 51 diarrhea predominant irritable 51 Aplidin 51 neuroprotective properties 51 selective adenosine 51 HZT 51 registrational trial 51 JAK inhibitors 51 tolerability 51 CLL SLL 51 metaglidasen 51 LY# [002] 51 PORxin TM 51 randomized controlled Phase 51 AAG geldanamycin analog 51 REVIVE Diabetes 51 docetaxel Taxotere R 51 MGd 51 anticancer compound 51 Pradefovir 51 2 methoxyestradiol 51 Cannabinor 51 Enzastaurin 51 Tezampanel 51 dasatinib Sprycel ® 51 TLR9 agonist 51 Elagolix 51 treatment naïve genotype 51 INC# 51 brivaracetam 51 mGluR5 negative 51 Xeloda ® 51 histone deacetylase inhibitor 51 entinostat 51 Phase IIb clinical trials 51 Firazyr 50 preclinical studies 50 EURIDIS 50 NGX# 50 pharmacokinetics pharmacodynamics 50 Cloretazine R VNP#M 50 Serdaxin 50 telaprevir VX 50 systemically administered 50 multicentre randomized 50 Phase III Clinical Trials 50 intravenously administered 50 ALTU 50 registrational 50 ToGA 50 hyperphenylalaninemia HPA due 50 posaconazole 50 HBeAg positive 50 Lubiprostone 50 Phase IIb clinical 50 imatinib Gleevec ® 50 pharmacodynamic profiles 50 DU #b 50 Ocrelizumab 50 EndoTAG TM -1 50 DDP# 50 SANTE 50 ALGRX 50 mTOR inhibitor 50 humanized anti 50 brostallicin 50 dosage regimens 50 JAK2 inhibitor 50 relapsed refractory multiple myeloma 50 Clevudine 50 Anticalin R 50 DOS# 50 lorvotuzumab mertansine 50 Pharmacokinetic 50 sJIA 50 CLORETAZINE TM VNP#M 50 Anticalin ® 50 SRT# [003] 50 highly selective adenosine 50 MNTX 50 Plicera 50 EGFR HER2 50 active comparator 50 radiolabeled monoclonal antibody 50 vemurafenib 50 Phase 2b Clinical Trial 50 Phase 2a clinical trials 50 receptor agonist 50 ritonavir boosted 50 antisense oligonucleotide 50 CANCIDAS 50 iSONEP 50 CB1 antagonists 50 dose escalation study 50 OncoVEX GM CSF 50 CLARITY study 50 darunavir ritonavir 50 CCX# B 50 Panzem R NCD 50 Liprostin 50 IAP inhibitor 50 anti angiogenic agent 50 Teriflunomide 50 Dacogen decitabine 50 Pharmacokinetics PK 50 mGluR2 NAM 50 receptor antagonist 50 dyskinesia PD LID 50 Multiple Ascending Dose 50 selective kinase inhibitor 50 RhuDex R 50 GRNVAC1 50 Sapacitabine 50 PDX pralatrexate 50 dihydrochloride 50 lomitapide 50 Phase IIb trial 50 OMNARIS HFA 50 Marqibo 50 Phase 2a 50 Corlux 50 tiapamil 50 rALLy clinical trial 50 PREZISTA r 50 Telintra 50 oral FTY# 50 forodesine 50 SAR# [002] 50 relapsing remitting multiple sclerosis 50 Fc fusion protein 50 small molecule chemotherapeutic 50 GLPG# 50 oral nucleoside analogue 50 pharmacodynamics 50 tocilizumab 50 Phase Ib clinical trials 50 CXA 50 novel VDA molecule 50 phase III isavuconazole 50 SAR# [004] 50 rNAPc2 50 SYN# 50 orally administered 50 dosing cohort 50 Raptiva ® 50 MGCD# [001] 50 dextromethorphan quinidine 50 LUX Lung 50 Phase IIa 50 dosing cohorts 50 Epratuzumab 50 EXPAREL TM 50 Degarelix 50 Aplidin R 50 dasatinib Sprycel 50 PHX# 50 CIMZIA TM 50 EndoTAG 50 ORENCIA ® 50 Fx #A 50 elacytarabine 50 subcutaneously administered 50 immunomodulating 50 investigational monoclonal antibody 50 FOLOTYN ® 50 multicenter randomized 50 adalimumab Humira 50 Factor VIIa 50 Janus Kinase 50 IDX# 50 Phase 1a 50 ATL/TV# 50 oral ridaforolimus 50 CCR9 antagonist 50 acyclovir Lauriad R 50 Proxinium TM 50 Irinotecan 50 AP# [003] 50 galiximab 50 Phase #b/#a clinical 50 Initiated Phase 50 zanolimumab 50 UPLYSO 50 bosutinib 50 aurora kinase 50 trastuzumab Herceptin R 50 pharmacodynamic 49 Zoraxel 49 NS4A 49 refractory chronic lymphocytic 49 pharmacokinetic 49 pharmacokinetic profile 49 allosteric modulator NAM 49 tyrosine kinase inhibitor 49 XmAb# 49 lenalidomide Revlimid R 49 Dose Ranging Study 49 cetuximab Erbitux R 49 PrevOnco 49 melphalan prednisone 49 Nexavar sorafenib 49 2 inhibitor CYT# 49 Double Blind Placebo 49 isoform selective 49 EVIZON ™ 49 investigational immunotherapy 49 amifampridine phosphate 49 NS#/#A protease 49 tanespimycin 49 Phase 2b study 49 somatostatin analogue 49 incyclinide 49 DB# [003] 49 TG MV 49 Ophena TM 49 TAXUS ATLAS 49 aleglitazar 49 alpha 2b 49 Betaferon ® 49 Adalimumab 49 miconazole Lauriad ® 49 peripherally acting 49 Anthim 49 interferon IFN 49 dacetuzumab 49 double blind placebo 49 inhaled liposomal ciprofloxacin 49 huC# DM4 49 II Clinical Trial 49 Epanova 49 XP #L 49 Aurora kinase 49 oral proteasome inhibitor 49 angiogenesis inhibitor 49 multicenter Phase 49 cyclin dependent kinase inhibitor 49 NP2 Enkephalin 49 RE LY ® 49 triciribine phosphate monohydrate 49 Troxatyl 49 OvaRex 49 CDP# 49 Triapine R 49 thorough QT 49 Urocidin 49 humanized antibody 49 reslizumab 49 VA# [002] 49 Panzem NCD 49 Kinase Inhibitor 49 pegylated interferon alfa 2a 49 Azixa 49 safety tolerability pharmacokinetics 49 RDEA# 49 evaluating REVLIMID 49 targeted antifolate 49 Zorbtive TM 49 cangrelor 49 Sudhir Agrawal D.Phil 49 KSP inhibitors 49 rxRNA 49 Synavive 49 OvaRex MAb 49 epothilones 49 alfa 2a 49 personalized immunotherapy 49 phase III ACCLAIM 49 ADI PEG 49 bevirimat Study 49 compound ITMN 49 CB2 selective receptor agonist 49 aprepitant 49 Myelodysplastic Syndrome MDS 49 pharmacokinetic PK profile 49 HuMax HepC TM 49 baminercept 49 Cancidas 49 mixed dyslipidemia 49 telaprevir dosed 49 atrasentan 49 Phase IIB 49 CYT# QbG# 49 randomized Phase III 49 Phase III Clinical Trial 49 superficial bladder cancer 49 monotherapy 49 pan histone deacetylase 49 Octreolin 49 OHR/AVR# 49 cannabinor 49 double blinded placebo 49 dose cohorts 49 tolerability profile 49 humanised monoclonal antibody 49 Telcyta 49 ZACTIMA 49 compound AEZS 49 assessing T DM1 49 investigational antiplatelet agent 49 relapsed myeloma 49 fluticasone furoate 49 Tracleer R 49 topical formulation 49 placebo controlled clinical trials 49 oral Hsp# inhibitor 49 beta2 agonist 49 LibiGel Phase III 49 BIM #A# 49 novel anticancer 49 Aurexis 49 fluvastatin 49 placebo controlled Phase 49 TMC# C# 49 seliciclib 49 single ascending dose 49 KSP inhibitor 49 mGluR2 positive 49 nitazoxanide 49 Actilon 49 CALGB 49 OncoVex 49 alefacept 49 Trandolapril 49 Asentar 49 Randomized Double blind 49 DEB# 49 partial agonist 49 Initiate Phase 49 leukemia AML 49 XL# XL# 49 luteinizing hormone releasing 49 CINTREDEKIN BESUDOTOX 49 lintuzumab SGN 49 APEX PD 49 opioid induced constipation 49 RSD# oral 49 EOquin TM 49 INCB# [002] 49 Phase III ALLEGRO 49 glucagon receptor 49 ARCOXIA 49 Vivecon 49 tolerability pharmacokinetics 49 poly ADP ribose polymerase 48 Aurora kinase inhibitor 48 HCV SPRINT 48 Pegasys ® 48 hypoxia activated prodrug 48 TREANDA 48 trabedersen 48 ruxolitinib 48 Protelos 48 BCR ABL inhibitor 48 CYT# potent vascular disrupting 48 leukemia CLL 48 androgen receptor antagonist 48 Dasatinib 48 Bronchitol 48 TELINTRA 48 CRF1 receptor antagonist 48 Bicifadine 48 ALN PCS 48 tramiprosate Alzhemed TM 48 LUMINATE 48 Phase 2b clinical 48 Ambrisentan 48 EXPLORE Xa 48 ORE# 48 Panzem 48 bicifadine 48 tolerated dose MTD 48 Phase III clinical 48 ribavirin RBV 48 Elocalcitol 48 BRIM3 48 acetonide FA 48 Arimoclomol 48 Prestara 48 TMC# r 48 ABSORB clinical 48 Pruvel 48 beclomethasone dipropionate 48 Cinquil 48 mg TID 48 Personalized Immunotherapy 48 midstage trials 48 efficacy tolerability 48 multicenter placebo controlled 48 BENICAR 48 refractory gout 48 Bortezomib 48 ZYBRESTAT 48 AIR CF1 48 levodopa induced dyskinesia 48 potent inhibitor 48 FLT3 48 vosaroxin 48 TKM ApoB 48 tumor xenograft models 48 eosinophilic asthma 48 Phase III psoriasis 48 AZILECT R 48 vismodegib 48 tolvaptan 48 ALKS 48 controlled multicenter Phase 48 afamelanotide 48 administered subcutaneously 48 bupropion SR 48 Nimotuzumab 48 peritumoral brain edema 48 TLK# 48 TO AVOID PREGNANCY WHILE 48 alkylating agent 48 CRTX 48 generation purine nucleoside 48 pharmacokinetics 48 Ophena 48 ABSORB trial 48 Omapro 48 MSI #F 48 cytokine refractory 48 oral rivaroxaban 48 PI3K inhibitors 48 CORT # 48 controlled multicenter 48 ZYBRESTAT fosbretabulin 48 bevirimat 48 NM# [003] 48 apricitabine ATC 48 CLL8 48 adenoviral 48 Tasimelteon 48 TMC# [002] 48 CCR5 inhibitor 48 RTP #i 48 selective immunoproteasome inhibitor 48 IMGN# 48 Æterna Zentaris 48 Diabetic Macular Edema 48 Pivotal Study 48 Darinaparsin 48 Phase III metastatic melanoma 48 Phase IIb 48 Proellex TM 48 ProLindac 48 Randomized Double Blind Placebo 48 Initiates Phase 2b 48 blind randomized placebo 48 VEGF receptor 48 antisense drug 48 Epothilones 48 drug GLPG# 48 Avanafil 48 Posiphen 48 pimecrolimus cream 48 HuMax CD# 48 PEG PAL 48 Phase III trials 48 developing Bicifadine serotonin 48 μg dose 48 small molecule tyrosine 48 Janus kinase 48 painful diabetic neuropathy 48 TH# [003] 48 docetaxel chemotherapy 48 Zerenex ™ 48 Familial Adenomatous Polyposis FAP 48 docetaxel Taxotere ® 48 lacosamide 48 Nuvion 48 afatinib 48 systemic RNAi therapeutic 48 NCCTG 48 potently inhibit 48 GATTEX ® 48 demonstrated antitumor activity 48 HCV infected 48 BENICAR HCT 48 Gleevec imatinib mesylate 48 Marqibo TM 48 nonclinical studies 48 label dose escalation 47 candesartan cilexetil 47 octreotide implant 47 CLARITY TIMI 47 TOLAMBA 47 secondary efficacy endpoints 47 T#I [002] 47 dexpramipexole 47 PEGylated Fab fragment 47 metastatic HRPC 47 GAMMAGARD 47 HuMax CD4 47 Alequel 47 label multicenter Phase 47 Friedreich Ataxia FRDA 47 plus gemcitabine 47 RRMS patients 47 Phase 2b trial 47 XL# XL# XL# 47 pitavastatin 47 fostamatinib 47 Diamyd R 47 MERLIN TIMI 47 Gleevec resistant 47 PLK1 SNALP 47 Phase III placebo controlled 47 Initiates Phase II 47 Multimeric 47 tacrolimus ointment 47 Anavex #-# 47 AGHD 47 meter freestyles 47 HMPL 47 multikinase inhibitor 47 Phase #b/#a 47 PEGINTRON TM 47 methionine aminopeptidase 47 Pagoclone 47 coadministration 47 Orphan Drug designations 47 QLT# 47 relapsed leukemia 47 chronic eosinophilic leukemia 47 N acetylgalactosamine 6 47 Anidulafungin 47 MAXY alpha 47 IFN Beta CTP 47 mg doses 47 canakinumab 47 investigational pan BCR 47 SPRYCEL ® 47 FOSRENOL R 47 HGS ETR2 47 plus prednisone 47 ENVISION 47 HepDirect prodrug 47 anticancer agent 47 kinase inhibitors 47 pramlintide 47 injectable formulation 47 acute coronary syndromes ACS 47 registrational Phase 47 randomized Phase IIb 47 Genz # 47 Cytochrome P# 47 ascending dose 47 NexACT 47 romidepsin novel 47 ONTARGET 47 refractory CLL 47 Onalta 47 Acute Coronary Syndromes ACS 47 protease inhibitors PIs 47 Junovan TM 47 brivanib 47 CERVARIX 47 dose pharmacokinetic 47 Zemplar Capsules 47 REYATAZ r 47 multicenter phase 47 Drug Candidate 47 Kevetrin 47 refractory multiple myeloma 47 Exelixis compounds 47 RhuDex TM 47 dose escalation clinical 47 TMC# [001] 47 Eltrombopag 47 invasive candidiasis 47 ADVANCE PD 47 volociximab 47 RhuDex 47 Dabigatran etexilate 47 azacitidine 47 XL# anticancer compounds 47 randomized multicenter 47 IRX 2 47 gemcitabine Gemzar ® 47 prospective randomized multicenter 47 efavirenz EFV 47 Tykerb lapatinib 47 sodium glucose transporter 47 cutaneous T cell 47 rasagiline tablets 47 selective modulator 47 myelodysplastic myeloproliferative diseases 47 IIa trial 47 TNF Tumor Necrosis Factor 47 tafamidis 47 confirmatory Phase 47 Linagliptin 47 ISTODAX